There are currently 2694 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
NCT05005975
Recruiting
To evaluate the long-term safety and tolerability of oral dersimelagon.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
04/20/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: EPP, XLP
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
Prospective Study to Validate the Imaging Biomarker for NCP (R33)
NCT05653921
Recruiting
The aim of this study is establish the reliability and clinical utility of microneuromas as identified via in vivo confocal microscopy as the diagnostic biomarker for NCP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Dry Eye Syndromes, Corneal Disease
Register for Updates
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: Boston Clinical Trials, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
NCT04468360
Recruiting
Purpose: About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experiences, stress, and genetics can affect treatment responses. These factors can alter brain capacities needed to reprocess traumatic memories prevent them from triggering intensely distressing, disruptive, out-of-place respons... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/18/2025
Locations: Boston University School of Medicine, Boston, Massachusetts
Conditions: Post Traumatic Stress Disorder
Register for Updates
Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT06118086
Recruiting
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Dana Farber Cancer Research Institute, Boston, Massachusetts
Conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Register for Updates
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
NCT05111561
Recruiting
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). ZEN003694 is an oral medication with potential anticancer activity. It is an inhibitor of a family of proteins called bromodomain and extra-terminal (BET) which play important role during development and c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Advanced Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
IVIG for Infection Prevention After CAR-T-Cell Therapy
NCT05952804
Recruiting
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hematologic Malignancies
Register for Updates
Study of REM-422 in Patients With AML or Higher Risk MDS
NCT06297941
Recruiting
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
Register for Updates
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT06322342
Recruiting
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis. The goal of this study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging. A single dose of RVP-001 will be administered to each subject. Subj... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/18/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma
Register for Updates
Immune Responses to Gluten
NCT05209568
Recruiting
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
Gender:
ALL
Ages:
Between 2 years and 101 years
Trial Updated:
04/18/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Celiac Disease, Malabsorption Syndromes, Digestive System Disease, Intestinal Disease, Gastrointestinal Diseases, Gluten Sensitivity, Celiac Disease in Children
Register for Updates
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
NCT06945614
Recruiting
The goal of this clinical study is to evaluate safety of Xenon gas inhalation in healthy volunteers. This first phase safety clinical study is part of evaluation of the xenon gas inhalation as a therapy for neurodegenerative diseases, such as Alzheimer's disease. The investigators will administer xenon gas in low concentration to people via anesthetic machine, observe participants for sedation and any unexpected side effects, collect blood at each visit and measure the vital signs. There are fo... Read More
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
04/18/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Healthy Volunteer Study
Register for Updates